# US 2025/0375424 A1 · Tinostamustine for use in treating sarcoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375424 A1
- Document ID: US20250375424A1
- Status: Published application
- Kind: A1
- Application number: 19/066,910
- Filed: 2025-02-28
- Published: 2025-12-11
- Earliest claimed: 2017-06-13
- Assignees: Purdue Pharma L.P.
- Applicants: Purdue Pharma L.P.
- Inventors: Thomas Jorg Mehrling
- Web page: https://patentgrep.com/patent/US20250375424A1

## CPC

- A61K 31/4184: condensed with carbocyclic rings, e.g. benzimidazoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There is provided tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma in a patient in need thereof.

## Claims

### Claim 1

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma in a patient in need thereof selected from soft tissue sarcoma, bone sarcoma or non-KIT gastrointestinal stromal tumour (GIST).

### Claim 2 (depends on 1)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 1 wherein the sarcoma is from the Ewing family of tumours.

### Claim 3 (depends on 2)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 2 wherein the sarcoma is Ewing tumour of bone.

### Claim 4 (depends on 2)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 2 wherein the sarcoma is extraosseous Ewing tumour.

### Claim 5 (depends on 2)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 2 wherein the sarcoma is primitive neuroectodermal tumour (PNET).

### Claim 6 (depends on 1)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 1 wherein the sarcoma is liposarcoma.

### Claim 7 (depends on 6)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 6 wherein the liposarcoma is well-differentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma, or dedifferentiated liposarcoma.

### Claim 8 (depends on 6)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 6 wherein the liposarcoma is dedifferentiated liposarcoma.

### Claim 9

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any preceding claim, wherein the cancer is relapsed and/or refractory.

### Claim 10

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any preceding claim, wherein tinostamustine or a pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof at a dosage level of from 0.3 to 300 mg/m2 body surface area of the patient, of from 60 to 150 mg/m2 body surface area of the patient, or of from 80 to 100 mg/m2 body surface area of the patient.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any one of claims 1 to 10, wherein tinostamustine or a pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof on days 1, 8 and 15 of a 28 day treatment cycle, or on days 1 and 15 of a 28 day treatment cycle.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any one of claims 1 to 11, wherein tinostamustine or a pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof over an infusion time of 60 minutes; or an infusion time of 45 minutes; or an infusion time of 30 minutes.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any one of claims 1 to 12, wherein tinostamustine or a pharmaceutically acceptable salt thereof is administered intravenously to the patient in need thereof at a dosage level of from 80 mg/m2 to 100 mg/m2 body surface area of the patient, on days 1 and 15 of a 28 day treatment cycle, and over an infusion time of 60 minutes.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to any one of claims 1 to 13, wherein the patient is treated with tinostamustine or a pharmaceutically acceptable salt thereof and radiotherapy

### Claim 15 (depends on 14)

Tinostamustine or a pharmaceutically acceptable salt thereof for use in the treatment of sarcoma according to claim 14, wherein said radiotherapy treatment is given to the patient in need thereof at a dose of 1 to 5 Gy over 5-10 consecutive days, and preferably 2 Gy over 5-10 consecutive days.

### Claim 16

A kit comprising tinostamustine or a pharmaceutically acceptable salt thereof together with instructions for treating sarcoma selected from soft tissue sarcoma, bone sarcoma or non-KIT gastrointestinal stromal tumour (GIST).
